On March 15, 2023 OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive therapy company developing innovative medications to address unmet needs in oncodermatology and oncogastroenterology (cancer therapy-induced side effects occurring in the skin and gastrointestinal tract) and to improve the quality of life for patients receiving anticancer medications, reported it will present preclinical data for its two drug candidates, OQL025 and OQL06x, at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting (Press release, OnQuality Pharmaceuticals, MAR 15, 2023, View Source [SID1234628843]). The conference will be held in Orlando, FL, April 14-19, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

EGFR inhibitors are a class of drugs commonly used in the treatment of various cancers, including lung and colorectal. However, EGFR inhibitors can lead to dose-limiting skin toxicities and/or diarrhea in some patients.

The most common skin toxicity associated with EGFR inhibitors is acneiform rash, which frequently appears on the face, neck, upper chest, and back. The incidence ranges from 20% to over 90% among patients receiving these drugs.

The incidence of EGFR inhibitor-induced diarrhea ranges from 40% to 90% depending on the specific agent and dose. The severity of diarrhea can also vary, with some patients experiencing moderate or severe diarrhea that can lead to dehydration, electrolyte imbalance, and other serious complications. Cancer patients experiencing diarrhea have a 40% higher therapy discontinuation rate compared to those who do not.

To address this significant unmet need, OnQuality is developing OQL025 and OQL06x. OQL025 is a novel topical cream, and OQL06x a gut-restricted JAK inhibitor.

"OQL025 and OQL06x are first-in-disease drug candidates for EGFR inhibitor-induced skin rash and diarrhea." said Robert C. Tyler, Ph.D., Senior Medical Director of OnQuality. "I am looking forward to sharing the data at the conference."

Abstract Information:

Title: OQL025, a topical cream for the prevention of epidermal growth factor receptor inhibitor-induced skin rash
Presented By: Robert C. Tyler, Ph.D.
Session Category: Clinical Research Excluding Trials
Session Title: Cancer Outcomes 1
Session Date and Time: Monday Apr 17, 2023 1:30 PM – 5:00 PM
Abstract Number: 3211

Title: OQL06x, a gut-restricted janus kinase inhibitor to control epidermal growth factor receptor inhibitor-induced diarrhea
Presented By: Robert C. Tyler, Ph.D.
Session Category: Clinical Research Excluding Trials
Session Title: Cancer Outcomes 1
Session Date and Time: Monday Apr 17, 2023 1:30 PM – 5:00 PM
Abstract Number: 3212